Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.5K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.

Blood neoplasia·2026
Same author

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Blood advances·2026
Same author

Imatinib-induced rhabdomyolysis: A case report.

Leukemia research reports·2026
Same author

Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.

The Journal of allergy and clinical immunology·2025
Same author

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.

Cancer cell·2025
Same author

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Related Experiment Video

Updated: Dec 26, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Targeted Alpha-Particle Therapy for Hematologic Malignancies.

Joseph G Jurcic1

  • 1Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center; Herbert Irving Comprehensive Cancer Center, and New York-Presbyterian Hospital, New York, NY.

Seminars in Nuclear Medicine
|March 17, 2020
PubMed
Summary

Targeted alpha-particle therapy (TAT) shows promise for hematologic malignancies, particularly acute myeloid leukemia (AML). Clinical trials with actinium-225-lintuzumab demonstrate safety and efficacy, with significant remission rates in AML patients.

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Related Experiment Videos

Last Updated: Dec 26, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.5K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Hematology

Background:

  • Targeted alpha-particle therapy (TAT) utilizes alpha particles' short range and high linear energy transfer for efficient tumor cell killing while sparing normal cells.
  • Hematologic malignancies are well-suited for TAT due to accessible malignant cells and inherent radiosensitivity.
  • Bismuth-213, actinium-225, astatine-211, and thorium-227 are radionuclides explored for TAT, with actinium-225 showing clinical promise.

Purpose of the Study:

  • To evaluate the safety and efficacy of targeted alpha-particle therapy using actinium-225-labeled lintuzumab in patients with acute myeloid leukemia (AML).
  • To assess the antileukemic activity and remission rates associated with different dosing regimens of 225Ac-lintuzumab in AML.
  • To explore the potential of TAT in intensifying therapy prior to hematopoietic cell transplantation and the role of pretargeting strategies.

Main Methods:

  • Clinical trials involving phase I and phase II studies of actinium-225-lintuzumab (225Ac-lintuzumab) in patients with AML.
  • Administration of single and fractionated doses of 225Ac-lintuzumab, often in combination with cytarabine.
  • Evaluation of safety, tolerability, dose-limiting toxicities, and antileukemic activity, including remission rates.

Main Results:

  • A single infusion of 225Ac-lintuzumab was safe up to 111 kBq/kg, demonstrating antileukemic activity.
  • Fractionated dosing of 225Ac-lintuzumab combined with low-dose cytarabine produced objective responses in 28% of older, untreated AML patients.
  • Monotherapy with 225Ac-lintuzumab achieved remission in 69% of patients receiving two 74 kBq/kg fractions and 22% receiving two 55.5 kBq/kg fractions.

Conclusions:

  • Actinium-225-lintuzumab is a safe and effective targeted alpha-particle therapy for acute myeloid leukemia, showing significant remission rates.
  • Fractionated dosing strategies and combination therapies may enhance treatment outcomes in AML.
  • TAT holds potential for improving outcomes in AML, including its use as a bridge to hematopoietic cell transplantation.